Can You Take ARA-290 With Tirzepatide or Semaglutide?

The medications this page covers:

Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices because they are priced by dose. Compounded medications are not FDA approved.

ARA-290, also called cibinetide, is an eleven-amino-acid peptide whose sequence was taken from one helix of erythropoietin. It was engineered so that it does not bind the receptor pair that drives red cell production, and is described instead as engaging a second assembly, one erythropoietin receptor paired with the beta-common receptor (CD131), which the research group calls the innate repair receptor. Its human trials are small randomised phase 2 studies in sarcoidosis-associated small-fibre neuropathy and in type 2 diabetes with painful neuropathy. It is not a painkiller, not a hormone and not a weight medication.

Tirzepatide activates the GIP and GLP-1 receptors. It prompts insulin release when glucose is high, suppresses glucagon, slows gastric emptying and acts on appetite centres in the brain. See what is tirzepatide.

Most people asking this have type 2 diabetes, or are being treated for weight, and have burning, tingling or numbness in their feet. The live reference on ARA-290 is direct about the order of things: glycaemic control is the foundation of diabetic neuropathy care, and tirzepatide and semaglutide have large human trials behind them for glucose and weight, which ARA-290 does not. ARA-290 is a conversation about the nerve symptoms themselves, after the causes have been looked at.

The other causes of small-fibre neuropathy that are worth checking are testable: B12 deficiency, thyroid disease and poorly controlled glucose. If B12 is the issue, methylcobalamin is the more direct conversation. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

What the diabetes trial found

The 2015 phase 2 study in Molecular Medicine gave people with type 2 diabetes and painful neuropathy 28 days of daily subcutaneous ARA-290 or placebo, then followed them for a further month. Neuropathic symptoms on the PainDetect questionnaire improved in the treated group, corneal nerve fibre density increased in those who started with clearly reduced density, and HbA1c and lipid profiles improved compared with placebo. No safety issues were identified. It was small, run by the developer, and has not been replicated. Nobody in it was described as taking a GLP-1 medication, so it says nothing about the combination. The trial-by-trial detail is in ARA-290 benefits.

This is the part of the combination that deserves attention.

In one tirzepatide trial in adults with type 2 diabetes, blood glucose below 54 mg/dL occurred in 10.3% of those also taking a sulfonylurea against 2.1% of those not. ARA-290 has no reported low blood sugar in the live sources, but because of its HbA1c finding, the ARA-290 references ask anyone on glucose-lowering medication to tell their physician. With both on board, that matters twice.

If you notice shakiness, sweating, sudden hunger or confusion that could be low blood sugar, treat it first, then tell your care team. Never change your own dose of anything in response; any change your physician makes is printed on your next vial.

Two separate facts sit near each other here. The tirzepatide label flags that people with existing diabetic retinopathy can see temporary worsening when glucose improves quickly, and asks that they be monitored. Separately, a 2020 open-label study gave nine people with diabetic macular oedema twelve weeks of daily cibinetide and found no improvement in visual acuity or retinal thickness, though the course was safe. So ARA-290 is not a treatment for diabetic eye disease, and if you have retinopathy, say so on your intake and keep your eye specialist informed.

Use a separate fresh syringe for each and never draw both into one. Both are subcutaneous, into the fat layer of the abdomen or thigh, with sites rotated. There is no logic to injecting ARA-290 near the feet or a painful area, because the mechanism described is systemic. Dosing detail is in ARA-290 dosage and tirzepatide dosing chart; technique is in how to inject peptides safely.

Start one thing at a time

Tirzepatide side effects are mostly gastrointestinal and cluster after starting and after each step up. ARA-290's reported effects in practice are mostly at the injection site.

Starting ARA-290 away from a tirzepatide dose increase means any change has one plausible cause. GLP-1 nausea is managed through portion size, meal composition and titration pace, covered in GLP-1 nausea: how to manage it. ARA-290 plays no part in that.

Everything above applies to semaglutide. It also lowers glucose, its common side effects are gastrointestinal for the same reason, and the same care with insulin or a sulfonylurea applies. Semaglutide and tirzepatide are never taken together. See semaglutide side effects.

ARA-290 has more human evidence than most compounded peptides: randomised, placebo-controlled phase 2 trials that reported improved neuropathy symptom questionnaires and increased corneal nerve fibre density after four weeks. They were small, short and run by the developer, and pain-intensity scores did not clearly separate from placebo. Nothing in them tested ARA-290 alongside a GLP-1, and nothing shows that ARA-290 changes weight, appetite or tirzepatide's side effects. What can be said is that the two act on unrelated receptors, no interaction is described, and both touch glucose in their own way. The safety detail is in ARA-290 side effects and tirzepatide side effects.

Where the FDA stands

As of the FDA's 14 May 2026 update, cibinetide (ARA-290) is in Category 3 of substances nominated for the 503A bulks list, "Bulk Drug Substances Nominated Without Adequate Support." That is a paperwork category, not a safety finding. It is not on the Category 2 list of substances that raise significant safety risks. It is prescription-only and compounded, and it is not FDA approved.

1. Name the reason. Say what the nerve symptoms are and how long you have had them.
2. List everything at intake. Include insulin, any sulfonylurea or other glucose-lowering medication, and any eye condition.
3. Start one thing at a time. Begin ARA-290 away from a GLP-1 dose increase.
4. Report what happens, including nothing. Your care team is reachable through your account.

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance. Step-by-step pages: how to get ARA-290 prescribed online and how to get tirzepatide prescribed online.